Research Highlights:

  • In primary care, sex differences for recommended cardiovascular (CVD) prescriptions were found for patients who were at high risk or who had CVD.
  • Women were less likely than men to receive cholesterol-lowering medicines and aspirin, yet equally likely to receive blood-pressure-lowering medications.

Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, May 20, 2020                                                                                                                   

DALLAS, May 20, 2020 — Women receiving treatment in primary care received some cardiovascular medication prescriptions at a lower rate than men, according to new research published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

“Additional efforts need to be taken to ensure that everyone, women and men, who should receive cardiovascular medications are actually prescribed these medications,” said lead study author Sanne Peters, Ph.D., research fellow in epidemiology at the George Institute for Global Health at the University of Oxford in the United Kingdom and associate professor at the University Medical Center Utrecht in the Netherlands. “We also need to reduce the persistent treatment gaps between women and men.”

Cardiovascular disease (CVD) is the leading cause of death worldwide. Lifestyle changes, including maintaining a healthy weight, quitting smoking, being physically active, eating a healthy diet, controlling high blood pressure and cholesterol, and reducing high blood sugar, can lower heart disease risk. “For some people, however, medication also may be necessary to reduce risk,” Peters noted.

Previous research among heart attack survivors found that women were less likely to receive recommended medications in a hospital setting. In this study, researchers wanted to understand whether this occurs even earlier, in primary care and among patients at high risk or with existing cardiovascular disease.

A systematic review of two large medical databases was conducted to find studies with data showing the number of cardiovascular-disease prescriptions among men and women. Researchers looked specifically for studies with data on statin prescriptions, which lower cholesterol; aspirin, which decreases the risk of blood clots; and blood-pressure lowering medications, including ACE-inhibitors and diuretics.

A total of 43 international studies with data on primary-care prescriptions among more than 2.2 million patients (28% women; average age 51-76 years) who were at risk for heart attack were evaluated. Among the findings, the analysis indicates women received:

  • 19% fewer aspirin prescriptions than men;
  • 10% fewer statin prescriptions than men; and
  • 15% fewer ACE-inhibitor prescriptions than men.

However, women were 27% more likely than men to be prescribed diuretics.

“Patients should talk with their physicians about the benefits of using heart disease medications and weigh them against the potential risks,” Peters said.

This analysis had limitations. For example, it could not control for differences in the 43 separate studies, and there was limited information about combined medications or other health conditions in addition to heart disease. Finally, the researchers examined sex differences in prescriptions only, not the effects of these differences on cardiovascular risk and events.

Co-authors are Min Zhao, Ph.D.; Mark Woodward, Ph.D.; Ilonca Vaartjes, Ph.D.; Elizabeth R.C. Millett, Ph.D. (deceased); Kerstin Klipstein-Grobusch, Ph.D.; Karice Hyun, Ph.D.; and Cheryl Carcel, M.D., Ph.D.

The Netherlands Organization for Scientific Research, the National Health and Medical

Research Council, the Dutch Heart Foundation, the National Heart Foundation Australia and the UK Medical Research Council supported the study.

Additional Resources:

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on, Facebook, Twitter or by calling 1-800-AHA-USA1


For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

William Westmoreland: 214-706-1232,

For Public Inquiries: 1-800-AHA-USA1 (242-8721) and